Cargando…

Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma

Aim of this study was to validate the prognostic impact of clinical parameters and baseline (18)F-FDG-PET/CT derived textural features to predict histopathologic response and survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiation (nCRT) and surgery. Betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Marr, Lisa, Haller, Bernhard, Pyka, Thomas, Peeken, Jan C., Jesinghaus, Moritz, Scheidhauer, Klemens, Friess, Helmut, Combs, Stephanie E., Münch, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065158/
https://www.ncbi.nlm.nih.gov/pubmed/35504955
http://dx.doi.org/10.1038/s41598-022-11076-0
_version_ 1784699524338417664
author Marr, Lisa
Haller, Bernhard
Pyka, Thomas
Peeken, Jan C.
Jesinghaus, Moritz
Scheidhauer, Klemens
Friess, Helmut
Combs, Stephanie E.
Münch, Stefan
author_facet Marr, Lisa
Haller, Bernhard
Pyka, Thomas
Peeken, Jan C.
Jesinghaus, Moritz
Scheidhauer, Klemens
Friess, Helmut
Combs, Stephanie E.
Münch, Stefan
author_sort Marr, Lisa
collection PubMed
description Aim of this study was to validate the prognostic impact of clinical parameters and baseline (18)F-FDG-PET/CT derived textural features to predict histopathologic response and survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiation (nCRT) and surgery. Between 2005 and 2014, 38 ESCC were treated with nCRT and surgery. For all patients, the (18)F-FDG-PET-derived parameters metabolic tumor volume (MTV), SUVmax, contrast and busyness were calculated for the primary tumor using a SUV-threshold of 3. The parameter uniformity was calculated using contrast-enhanced computed tomography. Based on histopathological response to nCRT, patients were classified as good responders (< 10% residual tumor) (R) or non-responders (≥ 10% residual tumor) (NR). Regression analyses were used to analyse the association of clinical parameters and imaging parameters with treatment response and overall survival (OS). Good response to nCRT was seen in 27 patients (71.1%) and non-response was seen in 11 patients (28.9%). Grading was the only parameter predicting response to nCRT (Odds Ratio (OR) = 0.188, 95% CI: 0.040–0.883; p = 0.034). No association with histopathologic treatment response was seen for any of the evaluated imaging parameters including SUVmax, MTV, busyness, contrast and uniformity. Using multivariate Cox-regression analysis, the heterogeneity parameters busyness (Hazard Ratio (HR) = 1.424, 95% CI: 1.044–1.943; p = 0.026) and contrast (HR = 6.678, 95% CI: 1.969–22.643; p = 0.002) were independently associated with OS, while no independent association with OS was seen for SUVmax and MTV. In patients with ESCC undergoing nCRT and surgery, baseline (18)F-FDG-PET/CT derived parameters could not predict histopathologic response to nCRT. However, the PET/CT derived features busyness and contrast were independently associated with OS and should be further investigated.
format Online
Article
Text
id pubmed-9065158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90651582022-05-04 Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma Marr, Lisa Haller, Bernhard Pyka, Thomas Peeken, Jan C. Jesinghaus, Moritz Scheidhauer, Klemens Friess, Helmut Combs, Stephanie E. Münch, Stefan Sci Rep Article Aim of this study was to validate the prognostic impact of clinical parameters and baseline (18)F-FDG-PET/CT derived textural features to predict histopathologic response and survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiation (nCRT) and surgery. Between 2005 and 2014, 38 ESCC were treated with nCRT and surgery. For all patients, the (18)F-FDG-PET-derived parameters metabolic tumor volume (MTV), SUVmax, contrast and busyness were calculated for the primary tumor using a SUV-threshold of 3. The parameter uniformity was calculated using contrast-enhanced computed tomography. Based on histopathological response to nCRT, patients were classified as good responders (< 10% residual tumor) (R) or non-responders (≥ 10% residual tumor) (NR). Regression analyses were used to analyse the association of clinical parameters and imaging parameters with treatment response and overall survival (OS). Good response to nCRT was seen in 27 patients (71.1%) and non-response was seen in 11 patients (28.9%). Grading was the only parameter predicting response to nCRT (Odds Ratio (OR) = 0.188, 95% CI: 0.040–0.883; p = 0.034). No association with histopathologic treatment response was seen for any of the evaluated imaging parameters including SUVmax, MTV, busyness, contrast and uniformity. Using multivariate Cox-regression analysis, the heterogeneity parameters busyness (Hazard Ratio (HR) = 1.424, 95% CI: 1.044–1.943; p = 0.026) and contrast (HR = 6.678, 95% CI: 1.969–22.643; p = 0.002) were independently associated with OS, while no independent association with OS was seen for SUVmax and MTV. In patients with ESCC undergoing nCRT and surgery, baseline (18)F-FDG-PET/CT derived parameters could not predict histopathologic response to nCRT. However, the PET/CT derived features busyness and contrast were independently associated with OS and should be further investigated. Nature Publishing Group UK 2022-05-03 /pmc/articles/PMC9065158/ /pubmed/35504955 http://dx.doi.org/10.1038/s41598-022-11076-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Marr, Lisa
Haller, Bernhard
Pyka, Thomas
Peeken, Jan C.
Jesinghaus, Moritz
Scheidhauer, Klemens
Friess, Helmut
Combs, Stephanie E.
Münch, Stefan
Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title_full Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title_fullStr Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title_full_unstemmed Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title_short Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
title_sort predictive value of clinical and (18)f-fdg-pet/ct derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065158/
https://www.ncbi.nlm.nih.gov/pubmed/35504955
http://dx.doi.org/10.1038/s41598-022-11076-0
work_keys_str_mv AT marrlisa predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT hallerbernhard predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT pykathomas predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT peekenjanc predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT jesinghausmoritz predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT scheidhauerklemens predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT friesshelmut predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT combsstephaniee predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma
AT munchstefan predictivevalueofclinicaland18ffdgpetctderivedimagingparametersinpatientsundergoingneoadjuvantchemoradiationforesophagealsquamouscellcarcinoma